🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Neoadjuvant atezo in non-urothelial cancer subtypes led by Bernadett Szabados Barts Experimental Cancer Medicine Centre #ESMO23 . Firstly, the inconsistency in pathology review is problematic. Secondly, the responders in the sarcomatoid group was very high - as in renal cancer. These patients need IO at some point.

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

Patients with #prostatecancer managed with active surveillance who are treated with 5-ARI have a lower risk of disease progression. Other interventions require more studies to determine their efficacy and safety profile in men on AS authors.elsevier.com/sd/article/S25… Pawel Rajwa

🥁🥁Finally, #pembrolizumab significantly improved the overall survival after nephrectomy for localized #renalcancer in the KN564 study💥💥! Very good news for all #RCC patients!

🌟An incredible day at the YAU meeting in #EMUC23 Marseille! 🤝🗣️ Exciting opportunity to connect and discuss our ongoing and future projects in an interdisciplinary way. #YAU #EMUCMarseille #Collaboration #Penilecancer #Testicularcancer European Association of Urology (EAU)

Hi! A dear friend of mine asked me to fill out this survey for her PhD. Could you also help her out? The survey is about the importance of clinical coding in clinical practice. It took me around 8 min to complete. Thank you in advance!🙏 Survey's link 👇 forms.gle/NUBA7wjXKSMtjv…

Breaking News: U.S. FDA approves Enzalutamide for non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence. ✅This landmark approval is based on the EMBARK trial, showing significant improvement in metastasis-free survival. 🤔What are your

🔘Disitamab Vedotin shows promising results in in Patients With HER2–Positive Locally Advanced or Metastatic Urothelial Carcinoma, with a 50.5% objective response rate and manageable safety profile. 🔘This could redefine #treatment protocols for those who've progressed on

🧬🧬🧬Erdafitinib has been shown to significantly improve survival times compared to chemotherapy in a recent phase 3 trial for those with advanced cases post anti-PD-1/PD-L1 treatment and with FGFR alterations! NEJM OncoAlert ylt ESMO - Eur. Oncology Jonathan Rosenberg MD Matt Galsky

🎉Hey urologists! 🎉 Our App is LIVE! Dive into our content anytime, anywhere - it's fast, easy, and at your fingertips! 📱 We're super excited to share this with you and we're open for your ideas to make it even more awesome! 💡 🚀📚 knowuro.com/subscription #Urology #MedTech

🚨don't miss: tomorrow: Inês Santiago, Walter Cazzaniga with other great panelists will discuss a case about Seminoma Stage IIB. What are the therapy options? Purple area, eURO auditorium 2 🟣 #EAU24

Happy to have presented an abstract about #prostatecancer and AI at #EAU24. OPTIMA Oncology Knowuro I'm looking forward to the future! #urology

Important project milestones achieved with the following: 💡 Develop care pathways 💡Finalise the guideline assessment 💡Develop typical case presentations Great work: Imran Omar @beyer_katharina Inês Santiago Anders Bjartell James N'Dow

#AUA24 Amer. Urol. Assn. plenary session👉We discussed critical role of the PSMA PET scan in management of #ProstateCancer with biochemical recurrence (BCR), Current Rx with salvage RT, results of Embark & ongoing ARASTEP trial in PSMA-PET+BCR👇Stacy Loeb, MD OncoAlert UroToday.com

The 1st disitimab Vedotin (HER-2 MMAE ADC) & pembro showing 1st line response rates of 75% in HER 1-3+ UC. Toxicity profile looks distinct from EV (fatigue>skin). There is a global randomised phase 3 of DV & pembro vs standard chemotherapy. #ESMO24 Jonathan Rosenberg MD Matt Galsky

Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024 NEJM

Great overview on #cancer #chemotherapy OncoAlert Cancer Cell

🚨 Calling all Pathologists! 🧬🩸 The YAU Working Group Penile & Testis Cancer team invites you to take a quick 5-minute survey on gross/histopathological practices for sentinel lymph-node biopsies in Penile Cancer. 📊🧑‍🔬 Your insights are invaluable, and the survey is completely anonymous! 🔗 [Take

Is it time to re-classify urachal cancer as a GI rather than a GU malignancy? In npj Journals Precision Oncology, we show the genomic profile of this rare cancer is more similar to colorectal than bladder cancer. (1/2) Link: nature.com/articles/s4169…

💡Updated European Association of Urology (EAU) Guidelines on the Use of #Adjuvant Immune Checkpoint Inhibitors and #Subsequent Therapy for Renal Cell Carcinoma 👉europeanurology.com/article/S0302-… European Urology #JensBedke Yasmin Abu-Ghanem Laurence Albiges Umberto Capitanio Saeed Dabestani Milan Hora Tobias Klatte #TeeleKuusk